Clinical Trial Update: A Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 in the Treatment of Moderate to Severe Papulopustular Rosacea [Phase 3]

View source ↗

Summary

Phase 3 clinical trial completed evaluating long-term safety of topical FMX103 for moderate to severe papulopustular rosacea; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Papulopustular Rosacea

Drugs mentioned

• FMX103

Snippet

Sponsor: Vyne Therapeutics Inc. | Conditions: Papulopustular Rosacea | Phase 3 | Status: COMPLETED | Results posted: 2020-12-29